Teijin Pharma Limited

Joelle Le

Hiroaki Makino

Kenichiro Kataoka

Minoru Imai

Gen Unoki

Tomomi Kosugi

Yuko Yamakoshi

Mika Takakuwa

Satoshi Sugiura

Dale Mitchell

Donald James Simpson

Naotaka Suzuki

Yasuhiro Oue

John Clifford Harris

Clifford John Harris

Aiko Fujino

Robert Dale Mitchell

James Donald Simpson

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-a]pyrimidine derivatives

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-A] pyrimidine derivatives

Growing community of inventors

Essex, United Kingdom

Joelle Le